# Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06167317/  
OnCo record `nct06167317` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT06167317 as recruiting, last updated 2026-08-13. Enrolment is 278 planned participants, an estimate. Interventions: GS-0201, Sacituzumab Govitecan. Primary measures include The Number of Participants with Dose Limiting Toxicities (DLTs) During Dose Escalation; The Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Registry id: NCT06167317
- Phase: 1
- Setting: A Phase 1 Study to Evaluate the Safety and Tolerability of GS-0201 as Monotherapy and in Combination in Adults With Advanced Solid Tumors
- Sponsor: Gilead Sciences

## Sources

- ClinicalTrials.gov NCT06167317: https://clinicaltrials.gov/study/NCT06167317

## Connected records

- targets: [PARP](https://onco.cc/targets/parp/), [TROP2](https://onco.cc/targets/trop2/)
- drugs: [GS-0201](https://onco.cc/drugs/gs-0201/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)

---
JSON: https://onco.cc/api/v1/entities/nct06167317.json